Effect of Natalizumab (Tysabri) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.

Trial Profile

Effect of Natalizumab (Tysabri) on Remyelination in Patients With Relapsing-remitting Multiple Sclerosis. A Follow-up Voxel-wise Magnetization Transfer Imaging Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Interferon beta-1a; Natalizumab
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Sep 2011 Actual end date November 2010 added as reported by ClinicalTrials.gov.
    • 06 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top